
# April 2017

# FORWARD LOOKING STATEMENT

This presentation includes statements that look forward in time or that express management's beliefs, expectations or hopes. Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's ability to transition to a biopharmaceutical company, and at an accelerated pace, the strength of the Company's patent portfolio, the Company's ability to take product currently used under Section 361 through the BLA process and obtain specific indications, the Company's ability to deliver P&L leverage in 2017 and beyond, the Company's ability successfully to develop new products and the timing and receipt of pending and anticipated regulatory clearances and approvals, the Company's plans for future product claims and studies in new markets, that the Company's investment in clinical trials will continue to help in gaining reimbursement coverage and regulatory approvals, the growth in the markets for the Company's current and future products and the share of such markets that the Company will be able to garner, the Company's ability to timely achieve the key 2017 milestones, and the Company's ability to achieve the milestones and financial projections in the "3 in 1 and 20" plan. Among the risks and uncertainties that could cause actual results to differ materially from those indicated-by such forward-looking statements include that the Company may be unable to transition to a biopharmaceutical company, or at an accelerated pace, physician acceptance of the Company's products for the uses anticipated by the Company may not occur at the expected pace or at all, there may be new challenges to the validity of the Company's patents or new incidences of infringement, the Company may not be able to expand its sales force as planned or the expansion may be delayed, the Company may be unable successfully to develop anticipated new products or the timing of such development may be delayed, the timing of anticipated regulatory clearances and approvals may be delayed or denied, there may be adverse regulatory actions against the Company, the Company's ongoing investment in clinical trials may not have the expected impact, the markets for the Company's current and future products may not be as large as the Company projects or grow as anticipated, the Company may not be able to achieve the market share it anticipates, including in the international market, the Company may face more effective competition, the Company may be unable to achieve the key 2017 milestone or achievement may be delayed, the Company may be unable to achieve the milestones and financial projections in the "3 in 1 and 20" plan, market demand for the Company's products may not grow or could decline, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2016. By making these forward-looking statements, the Company does not undertake to update, them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

# MIMEDX IS A BIOPHARMACEUTICAL COMPANY

- Global Company Delivering Innovative Placental Tissue Based Regenerative Therapies and Therapeutic Biologics that Restore Function and Improve Life
- On Track to Complete Transition into a Biopharmaceutical Company by 2020
- Lead Product Contains a Milieu of 226 Proteins with a Unified Mechanism of Action
- Extensive Placental Tissue Technology Patent Family Covers BLA Indications
- Strategic Plan to Triple 2015 Revenues to $560M and Deliver $1.00 of Adjusted Earnings in 2020 (3 and 1 in 20)
- Release Interim Phase 2b Data from Lead BLA Program in 3Q17 and Initiate Phase 3 Trial in 4Q17 or Early 2018
- Unique Opportunity to Take a Product Currently Used Under 361 Regulations Through the BLA Process for Two Specific Indications:
  - Plantar Fasciitis Pain / Tendonitis
  - Knee OA Pain

# WOUND CARE AND SSO MOMENTUM IS INCREASING

- Met or Exceeded Revenue Guidance in 24 of Last 25 Quarters
- 25 Consecutive Quarters of Sequential Revenue Growth
- Sustain 20%+ Revenue Growth Over the Long Term
- 86% Gross Margins and Strong Balance Sheet
- Deliver P&L Leverage in 2017 and Beyond



# KNEE OA IS A BOOMING EPIDEMIC WITH NO CURE


2015 U.S. Joint Pain Injection Market. SmartTRAK Business Intelligence and Company Estimates

# A NEW SAFE AND DURABLE TREATMENT OPTION FOR KNEE OA PAIN IS DESPERATELY NEEDED




* Toxic side effects and limited efficacy  ** Limited efficacy



MiMedx

# AMNIOFIX INJECTABLE IS AN INVESTIGATIONAL THERAPEUTIC THAT MAY OFFER INCREASED SAFETY AND EFFICACY



# PAIN MANAGEMENT CLINICAL TRIAL TIMELINES


NOTE With the new 21st Century Cures legislation and the potential Trump Administration FDA Commissioner nominees, there could be compression of this schedule.

# RESPIRATORY AND CARDIOVASCULAR UPDATE

- Respiratory System
  - Completing Drug Discovery and Design Process
  - Initiating Pre-Clinical Development Program
  - Current Goal is to begin Human Testing in 4Q 2018

- Cardiovascular System
  - Published Small Animal Study
  - Refining Development Program
  - Optimizing Delivery System

**Scanning Electron Microscope Slides of Respirable Particles**



# KEY 2017 MILESTONES

- ✓ **Positive Aetna Coverage Decision**

- **First Half 2017**
  - First Patent Infringement Trial
  - Report VLU Multicenter Data
  - Report DFU Multicenter Data

- **Mid-2017**
  - Plantar Fasciitis 2b Interim Data
  - Publish GI Anastomosis Data

- **Second Half 2017**
  - Publication VLU Multicenter Trial
  - Publication DFU Multicenter Trial
  - Report Prostatectomy Data
  - Knee OA Data

- **2017**
  - Additional “Reimbursement Wins”

- **2018**
  - Plantar Fasciitis Phase llb Data
  - Knee OA Data


MiMedx